Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among hiv-infected gold miners in South Africa

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Fielding, Katherine ^a   Koba, Ai ^a   Grant, Alison D ^a   Charalambous, Salome ^b   Day, John ^a,b   Spak, Cedric ^c   Wald, Anna ^c,d   Huang, Meei Li ^c   Corey, Lawrence ^c,d   Churchyard, Gavin J ^a,b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b AURUM INSTITUTE   (South Africa)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GOLD; VIRUS DNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MINER; MORTALITY; SOUTH AFRICA; VIREMIA; VIRUS LOAD; WORLD HEALTH ORGANIZATION; CYTOMEGALOVIRUS INFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MINING; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME; VIROLOGY;

CYTOMEGALOVIRUS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GOLD; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MINING; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SOUTH AFRICA; TIME FACTORS; VIREMIA;

EID: 80053939727     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025571     Document Type: Article

References (23)

1. Drew WL, (1992) Cytomegalovirus infection in patients with AIDS. Clin Infect Dis 14: 608-615.
2. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE, (1992) Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 166: 1223-1227.
3. Griffiths PD, (2006) CMV as a cofactor enhancing progression of AIDS. J Clin Virol 35: 489-492.
4. Webster A, Grundy JE, Lee CA, Emery VC, Cook DG, et al. (1989) Cytomegalovirus infection and progression to AIDS. Lancet 2: 681.
5. Robain M, Boufassa F, Hubert JB, Persoz A, Burgard M, et al. (2001) Cytomegalovirus seroconversion as a cofactor for progression to AIDS. AIDS 15: 251-256.
6. Kovacs A, Schluchter M, Easley K, Demmler G, Shearer W, et al. (1999) Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 341: 77-84.
7. Sabin CA, Phillips AN, Lee CA, Janossy G, Emery V, et al. (1995) The effect of CMV infection on progression of human immunodeficiency virus disease is a cohort of haemophilic men followed for up to 13 years from seroconversion. Epidemiol Infect 114: 361-372.
8. Jabs DA, Holbrook JT, Van Natta ML, Clark R, Jacobson MA, et al. (2005) Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 112: 771-779.
9. Wohl DA, Zeng D, Stewart P, Glomb N, Alcorn T, et al. (2005) Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies. J Acquir Immune Defic Syndr 38: 538-544.
10. Deayton JR, Prof Sabin CA, Johnson MA, Emery VC, Wilson P, et al. (2004) Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet 363: 2116-2121.
11. Erice A, Tierney C, Hirsch M, Caliendo AM, Weinberg A, et al. (2003) Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360). Clin Infect Dis 37: 567-578.
12. Spector SA, Wong R, Hsia K, Pilcher M, Stempien MJ, (1998) Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest 101: 497-502.
13. Bowen EF, Wilson P, Cope A, Sabin C, Griffiths P, et al. (1996) Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS 10: 1515-1520.
14. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, et al. (2002) Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 8: 362-369.
15. George B, Pati N, Gilroy N, Ratnamohan M, Huang G, et al. (2010) Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis 12: 322-329.
16. Day JH, Grant AD, Fielding KL, Morris L, Moloi V, et al. (2004) Does tuberculosis increase HIV load? J Infect Dis 190: 1677-1684.
17. Charalambous S, Grant AD, Day JH, Rothwell E, Chaisson RE, et al. (2004) Feasibility and acceptability of a specialist clinical service for HIV-infected mineworkers in South Africa. AIDS Care 16: 47-56.
18. Adjei AA, Armah HB, Gbagbo F, Boamah I, Adu-Gyamfi C, et al. (2008) Seroprevalence of HHV-8, CMV, and EBV among the general population in Ghana, West Africa. BMC Infect Dis 8: 111.
19. Boeckh M, Huang M, Ferrenberg J, Stevens-Ayers T, Stensland L, et al. (2004) Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 42: 1142-1148.
20. Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, et al. (2007) Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 196: 1500-1508.
21. Slyker JA, Lohman-Payne BL, Rowland-Jones SL, Otieno P, Maleche-Obimbo E, et al. (2009) The detection of cytomegalovirus DNA in maternal plasma is associated with mortality in HIV-1-infected women and their infants. AIDS 23: 117-124.
22. Micol R, Buchy P, Guerrier G, Duong V, Ferradini L, et al. (2009) Prevalence, risk factors, and impact on outcome of cytomegalovirus replication in serum of Cambodian HIV-infected patients (2004-2007). J Acquir Immune Defic Syndr 51: 486-491.
23. Kempen JH, Jabs DA, Wilson LA, Dunn JP, West SK, et al. (2003) Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin Infect Dis 37: 1365-1373.